1 Result: Neuronetics
Biotech Companies Report Q1 Results: Neuronetics Beats Consensus, Voyager Therapeutics Surpasses Expectations, Y-mAbs Therapeutics Outperforms Estimates
May 09th, 2023
Neuronetics, Inc. (Nasdaq: STIM) has reported a Q1 loss of $0.38 per share, which was slightly better than the consensus loss of $0.39 per share. As of this writing, $STIM is trading at $2.89, up by 31.36% or $0.69. Meanwhile, Voyager Therapeutics. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Due: Wall Street Eyes Goldman Sachs, Fastenal, FB Financial
April 12th, 2026Treasury Launches Cybersecurity Information Sharing Initiative for the Digital Asset Industry
April 09th, 2026How Eligibility Protection Is Creating New Opportunities for Football Athletes After High School
April 08th, 2026Cryptocurrency and AI Scams Bilk Americans of Billions
April 06th, 2026
Member Login